Skip to main content

Biosearch Expands License to Roche IVD Patents

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biosearch Technologies today said that it has expanded its license to certain Roche in vitro diagnostic patents, granting the firm rights to manufacture and sell validated kits covered by the Roche patents to the IVD market.

The kits Biosearch intends to sell will include probes, primers, enzymes, and any other essential reagents necessary to amplify and detect diagnostic targets. As a result, the Novato, Calif.-based firm will expand beyond being a provider of oligonucletoide components for molecular diagnostics to being a provider of diagnostic kits.

Last year, Biosearch had licensed a family of patents from Roche Molecular Systems covering uses of the 5' Nuclease process. It followed that up with a license from the US Centers for Disease Control and Prevention for patents covering the 2009 H1N1 and Influenza A Sub-typing signatures.

"With this expanded Roche license, Biosearch is poised to enter the IVD marketplace as a pivotal manufacturer of diagnostic kits," Marc Beal, director of corporate development at Biosearch Technologies, said in a statement.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.